Stock Analysts’ updated eps estimates for Wednesday, October 16th:

Abeona Therapeutics (NASDAQ:ABEO) had its buy rating reaffirmed by analysts at HC Wainwright. They currently have a $15.00 target price on the stock.

First Majestic Silver (NYSE:AG) (TSE:FR) had its buy rating reiterated by analysts at HC Wainwright. The firm currently has a $11.50 price target on the stock.

Amazon.com (NASDAQ:AMZN) had its outperform rating reissued by analysts at Credit Suisse Group AG. Credit Suisse Group AG currently has a $2,400.00 price target on the stock, up from their previous price target of $2,225.00.

Cascades (OTCMKTS:CADNF) had its hold rating reiterated by analysts at CIBC.

Eldorado Resorts (NASDAQ:ERI) had its buy rating reiterated by analysts at Deutsche Bank AG. The firm currently has a $66.00 target price on the stock.

Evofem Biosciences (NASDAQ:EVFM) had its overweight rating reissued by analysts at Cantor Fitzgerald. The firm currently has a $9.00 target price on the stock.

FARO Technologies (NASDAQ:FARO) had its hold rating reissued by analysts at Needham & Company LLC.

Gaming and Leisure Properties (NASDAQ:GLPI) had its buy rating reiterated by analysts at Deutsche Bank AG. Deutsche Bank AG currently has a $45.00 target price on the stock.

GIVAUDAN SA/ADR (OTCMKTS:GVDNY) had its neutral rating reissued by analysts at UBS Group AG.

Ionis Pharmaceuticals (NASDAQ:IONS) had its hold rating reaffirmed by analysts at Cowen Inc.

J B Hunt Transport Services (NASDAQ:JBHT) had its market perform rating reissued by analysts at Cowen Inc. The firm currently has a $108.00 target price on the stock, down from their previous target price of $113.00.

J B Hunt Transport Services (NASDAQ:JBHT) had its neutral rating reaffirmed by analysts at Credit Suisse Group AG. They currently have a $106.00 price target on the stock, up from their previous price target of $101.00.

PDF Solutions (NASDAQ:PDFS) had its buy rating reaffirmed by analysts at Northland Securities.

Zendesk (NYSE:ZEN) had its outperform rating reiterated by analysts at Wedbush. They currently have a $98.00 price target on the stock, down from their previous price target of $106.00. They noted that the move was a valuation call. The analysts noted that the move was a valuation call.

Receive News & Ratings for Abeona Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.